A study of the potential anticancer activity of *Mangifera zeylanica* bark: Evaluation of cytotoxic and apoptotic effects of the hexane extract and bioassay-guided fractionation to identify phytochemical constituents

MERAN KESHAWA EDIRIWEERA, KAMANI HEMAMALA TENNEKOON, SAMEERA RANGANATH SAMARAKOON, IRA THABREW and EGODAGE DILIP DE SILVA

1Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo; 2Department of Chemistry, Faculty of Science, University of Colombo, Colombo 00300, Sri Lanka

Received November 29, 2014; Accepted November 26, 2015

DOI: 10.3892/ol.2016.4087

**Abstract.** The present study investigated the potential anticancer activity of the bark of *Mangifera zeylanica*, an endemic plant in Sri Lanka that has been traditionally used for cancer therapy. Cytotoxic and apoptotic effects were investigated in vitro using sulforhodamine assay, acidine orange and ethidium bromide staining, caspase-3 and -7 activity, DNA fragmentation and reverse transcription-quantitative polymerase chain reaction in estrogen receptor positive MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines, SKOV-3 ovarian cancer cell line and MCF-10A normal mammary epithelial cells. Hexane extract demonstrated increased levels of cytotoxicity in cancer cells (IC_{50}, 86.6-116.5 µg/ml) compared with normal cells (IC_{50}, 217.2 µg/ml). Chloroform extract demonstrated increased cytotoxicity to normal cells (IC_{50}, 92.9 µg/ml) compared with cancer cells (IC_{50}, 280.1-506.5 µg/ml). Exposure to the hexane extract led to morphological changes characteristic of apoptosis and DNA fragmentation in the three cancer cell lines. Caspase-3 and -7 were significantly activated in MDA-MB-231 and SKOV-3 cells, indicating the occurrence of caspase-dependent apoptosis in these cells, and caspase-independent apoptosis in MCF-7 cells. Furthermore, upregulation of proapoptotic Bel-2-associated X protein occurred in the three cancer cell lines, and antiapoptotic survivin was down-regulated in MCF-7 and SKOV-3 cells; by contrast, tumor protein p53 was upregulated only in MCF-7 cells, suggesting p53-mediated apoptosis in MCF-7 cells and p53-independent apoptosis in the remaining cancerous cell lines. In addition, fraction M1 obtained from bioactivity-guided fractionation of the hexane extract demonstrated increased cytotoxicity in cancer cells (IC_{50}, 15.4-38.7 µg/ml) compared with normal cells (IC_{50}, 114.6 µg/ml), with the highest cytotoxicity observed in MDA-MB-231 triple-negative breast cancer cells. The hexane extract of *M. zeylanica* bark contained polyphenols and flavonoids, and caused free radical scavenging activity. Its gas chromatography-mass spectrometry profile revealed the presence of long-chain hydrocarbons, including β-sitosterol and β-amyrin. Fraction M1 contained seven unknown compounds and a small number of known non-cytotoxic compounds. Collectively, results obtained in the present study indicate that the hexane extract of *M. zeylanica* bark mediates cytotoxic activities through induction of apoptosis in three cancer cell lines; thus, the hexane extract may be used to isolate novel anti-cancer compounds.

**Introduction**

Breast cancer accounts for almost 1/4 of all cancers diagnosed in women (1). Among the molecular subtypes of breast cancer, estrogen receptor (ER)-positive subtypes respond to anti-estrogen therapy (2), but have been observed to develop resistance (3). Triple-negative breast cancer, which does not express ER, progesterone receptor or human epidermal growth factor receptor 2 (HER2), is more aggressive and has a reduced number of treatment options (4). Anti-estrogens and trastuzumab are not effective for the treatment of triple-negative cancer, as cells do not express ER or HER2 (5); therefore chemotherapy is the only effective treatment option (6). Besides being expensive, radiotherapy and chemotherapy may cause serious side effects (7). Therefore, it is necessary to discover novel anticancer compounds that cause fewer adverse effects. Plants and other natural sources have provided ~60% of anti-cancer agents currently in use (8); however, there are a number of traditionally used plants that remain to be scientifically validated.
Mangifera zeylanica (family, Anacardiaceae) is a plant endemic to Sri Lanka, and is typically found in the intermediate and wet zone forests (9). It is commonly known as ‘Etamba’, and grows as a wild species that bears edible fruit. M. zeylanica has been used traditionally for cancer therapy in Sri Lanka. However, these claims have not been scientifically validated. Mangiferin is the only reported compound isolated from M. zeylanica (10). Therefore, the present study was conducted to evaluate the potential cytotoxic and apoptotic effects of M. zeylanica on breast and ovarian cancer cells and to identify phytochemical constituents in active fractions obtained from bioactivity-guided fractionation.

Materials and methods

Plant material, chemicals, cell lines and cell culture reagents. Approval was obtained from the Department of Wildlife Conservation, Government of Sri Lanka (Columbo, Sri Lanka) for collecting M. zeylanica bark for research. The bark (2.5 kg) was collected from Imaduwa (Galle, Sri Lanka) and the plant was identified by a botanist at Bandaranayake Memorial Ayurvedic Research Institute (BMARI; Nawinna, Maharagama, Sri Lanka). The voucher specimen (#1221 A) was deposited at BMARI. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Cell lines and 10% fetal bovine serum were acquired from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Extraction and preparation of plant extract. Finely powdered dried bark (2.5 kg) was subjected to sequential extraction using hexane, chloroform, ethyl acetate and methanol (thrice with each solvent) by sonicating for 3 h at room temperature. All resulting extracts were filtered and evaporated using an R-3 rotary evaporator (BÜCHI Labortechnik AG, Flawil, Switzerland) under reduced pressure to 40°C to obtain crude extracts of hexane, chloroform, ethyl acetate and methanol. Stock solutions were prepared by dissolving in dimethyl sulfoxide (DMSO), and diluted to working solutions prior to use (the final DMSO concentration was 0.5% v/v).

Preliminary phytochemical analysis, determination of total flavonoid and polyphenol content and free radical scavenging activity. Hexane extract of M. zeylanica was tested for the presence of polyphenols (11), flavonoids (12), lipids, sterols and saponins (13,14) using previously described methods with minor modifications as required. Polyphenol content was expressed as gallic acid equivalent, and flavonoid content as quercetin equivalent, per 1 g of plant extract.

Free radical scavenging activity of the extract was investigated by 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay (15) with minor modifications. Hexane extract (0.5 ml) was added at various concentrations (25, 50, 100, 200 and 400 µg/ml) to 0.5 ml of DPPH (Sigma-Aldrich) solution (5.9 g in 100 ml methanol) and incubated in the dark for 30 min, followed by absorbance (A) reading at 517 nm (Synergy™ HT Multi-Mode Microplate Reader; Bio-Tek Instruments, Inc., Winooski, VT, USA). Percentage scavenging ability was calculated as half maximal effective concentration (EC₅₀) using the following equation: EC₅₀ = (A_control - A_sample)/A_control x 100. Ascorbic acid was utilized as the positive control.

Cell culture and cytotoxicity assay. MCF-7 human ER-positive breast cancer cells, MDA-MB-231 triple-negative breast cancer cells, SKOV-3 ovarian epithelial cancer cells and MCF-10A normal mammary epithelial cells were maintained in ATCC-recommended medium (MCF-7 cells, Dulbecco's modified Eagle's medium (DMEM; ATCC 30-2002); MDA-MB-231 cells: Leibovitz's L-15 medium (ATCC 30-2008); SKOV-3 cells, McCoy's 5A medium (ATCC 30-2007); and MCF-10A cells, DMEM (ATCC 30-2002)) with 10% fetal bovine serum, insulin (Sigma-Aldrich; 0.01 mg/ml), streptomycin (Sigma-Aldrich; 0.1 mg/ml) and penicillin (Sigma-Aldrich; 100 U/ml). All cells were cultured at 37°C in an atmosphere of 5% CO₂, with the exception of MDA-MB-231 cells, which were cultured without CO₂. Cells were harvested by trypsinization and seeded into 96-well plates (product no. 3860-096; Iwaki Cell Biology, Iwaki, Japan) at a density of 5x10³ cells/well. Following 24 h incubation, cells were treated with various doses (25, 50, 100, 200 or 400 µg/ml) of hexane, chloroform, ethyl acetate or methanol extracts, or mangiferin. The cytotoxic effect of the extracts was assessed by sulforhodamine B (SRB) assay following 24 h incubation (16). Briefly, cells were fixed using 50 µl of ice-cold 50% trichloroacetic acid, incubated for 60 min at 4°C, washed with tap water five times and stained using 0.4% SRB solution (100 µl stain/well). Plates were subsequently incubated at room temperature for 15 min, SRB solution was decanted and unbound dye was removed by washing with 1% acetic acid five times, followed by air-drying. Unbuffered Tris-base solution (200 µl/well) was added to the wells to solubilize unbound SRB dye. The contents were mixed on an agitator for 1 h at room temperature. Absorbance was read at optical density 540 nm (Synergy™ HT Multi-Mode Microplate Reader) and percentage cell viability was calculated (mean of control group - mean of treated group / control group x 100%). All experiments were performed in triplicate. Paclitaxel (Sigma-Aldrich) was utilized as the positive control. Negative controls received ATCC-recommended medium and DMSO.

Identification of active fractions of the M. zeylanica bark extract. The crude hexane extract, which was cytotoxic to cancer cells and less cytotoxic to normal cells, was subjected to a series of solvent-solvent partitions. It was initially partitioned using hexane-ethyl acetate (9:1, v/v) and subsequently, chloroform layer (1.1 g) was subjected to silica gel column chromatography (230-400 mesh; cat no. 3860-096; Labtech India Pvt. Ltd., Delhi, India) and eluted with 100 ml each of hexane-ethyl acetate (8:2, 7:3, 6:4, 1:1, 4:6, 3:7, 2:8, 1:9, v/v), ethyl acetate-methanol (1:1, v/v) and methanol. All the solvents for chromatography separations were purchased from Sigma-Aldrich. Active fractions identified by SRB assay were monitored by normal-phase thin-layer chromatography (TLC) using hexane-ethyl acetate (1:1, v/v) as the mobile phase. As
all cytotoxic fractions produced almost a clear spot during normal-phase TLC, all fractions were pooled and concentrated to give T₁. T₁ was monitored on reversed-phase TLC using methanol-water (9:5, v/v) as the mobile phase, fractionated in a reversed-phase column (C₁₈), and eluted with 10 ml each of methanol-water (7:3, 8:3, 9:3, v/v) and methanol. Fractions identified as most cytotoxic by SRB assay were monitored by reversed-phase TLC using methanol-water (9:1, v/v) as the mobile phase. Following observation of the behaviour of these fractions in reversed phase-TLC, 500 µl from each active fraction was pooled to give the final fraction (M₁) and its cytotoxicity to cancer cells and normal mammary epithelial cells was assessed.

**Evaluation of apoptotic effects.** The potential apoptotic effects of the hexane extract were assessed by investigating its effect on caspase-3 and -7 activity, morphological changes and DNA fragmentation. The effect on caspase-3 and -7 activity was determined in the three cancer cell lines. Cells were treated with the hexane extract for 4 h (25, 50, 100, 150 and 200 µg/ml) or 24 h (5, 10, 25, 50 and 100 µg/ml). Caspase activity was assessed using ApoFox-Glo™ triplex assay according to the manufacturer's protocol (Promega Corporation, Madison, WI, USA) and compared with untreated controls.

The three cancer cell lines (5x10⁴ cells/ml) were treated with 200 and 400 µg/ml of the hexane extract for 24 h and harvested by trypsinization and centrifugation. The resulting cell pellets were subsequently incubated for 1 h at 55°C in freshly prepared lysis buffer (5 mM Tris-HCl, pH 8; 1 M NaCl and 5 mM ethylenediaminetetraacetic acid, pH 8; 0.5% sodium dodecyl sulfate and proteinase K; 200 µg/ml). Following incubation with RNaseA (200 µg/ml) for 2 h at 50°C, DNA was extracted using phenol-chloroform-isooamyl alcohol. Extracted DNA was visualised under ultraviolet light to assess the effect on DNA fragmentation (Quantum-ST4 1100/20 M; Fisher Biotec Pty Ltd., Wembley, Australia) as the mobile phase, fractionated according to the manufacturer's protocol (Promega Corporation, Madison, WI, USA) and compared with untreated controls.

Table I. Primers used for reverse transcription-quantitative PCR and the PCR product size.

| Gene                  | Forward primer, 5’-3’ | Reverse primer, 5’-3’ | Size, bp |
|-----------------------|-----------------------|-----------------------|----------|
| Bcl-2-associated X protein | TCCAGGATCGAGCAGGGCGAAG | CGATGGCGTTGAGACACTCGCT | 109      |
| Tumor protein p53      | TCTGGCCCATTCCTAGCATTTT | TTGGGCACTGCTGCTTATGTC | 369      |
| Survivin              | TGGCCGCCTCCTTCCTAGAAAA | GCTGCTGCCCTCAAAGAAAGCG | 190      |
| GAPDH                 | GGCATTGCCCCTAAGCGACCAC | ACATGCAAGGTTGCGGCTCCCTA | 283      |

**Table II. Qualitative phytochemical screening of the hexane extract of Mangifera zeylanica.**

| Phytochemical          | Presence/absence |
|------------------------|------------------|
| Steroids               | ++++             |
| Flavonoids             | +                |
| Phenolic compounds     | ++++             |
| Tannins                | +                |
| Reducing sugars        | +                |
| Saponins               | -                |

++++, appreciable amount; +, low amount; -, not detectable.

RNA isolation and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). The three cancer cell lines (200,000 cells/ml) were cultured in cell culture flasks, treated with the hexane extract at 100 or 150 µg/ml for 4 h, and 50 or 75 µg/ml for 24 h. Following treatment, cells were harvested and total RNA was extracted with TRIzol® Reagent (Invitrogen; Thermo Fisher Scientific, Inc., Carlsbad, CA, USA) according to the manufacturer's protocol. Total extracted RNA (2 µg) and 50 ng of random primers (Integrated DNA Technologies, Coralville, USA) were mixed in a PCR tube (0.2 ml) and the total volume was made up to 13.5 µl with diethylpyrocarbonate (DEPC)-treated ultrapure water for reverse transcription. The resulting RNA-random primer mixture was denatured at 70°C for 5 min and subsequently quenched on ice for 2 min to prevent formation of secondary structures. Complementary (c)DNA was synthesized by adding 5 µl 5X buffer, 5 µl 10 mM deoxynucleotide mixture (deoxygenadenosine triphosphate, deoxyguanosine triphosphate, deoxyctydine triphosphate and deoxythymidine triphosphate), 25 units of RNasin and 200 units of Moloney murine leukaemia virus reverse transcriptase (all Thermo Fisher Scientific, Inc.), and the reaction mixture (25 µl) was incubated at 37°C for 60 min by using a thermal cycler. RT-qPCR was performed in Stratagene Mx3000P using the MESA Green qPCR Master Mix Plus for SYBR Assay (Eurogentec, Seraing, Liège, Belgium) with the primers listed in Table I (except for p53 in SKOV-3 cancer cells, which are p53-null; Integrated DNA Technologies). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was utilized as the housekeeping gene. The reaction
was performed in a total volume of 25 µl, containing 2 µl cDNA sample, 0.5 µl of each primer (0.5 µM), 12.5 µl SYBR Green reaction mix and DEPC-treated ultrapure water (9.5 µl). PCR amplification was performed in duplicate wells. The cycling conditions were as follows: Denaturation step (95°C for 10 min), and 40 cycles of three-step amplification (denaturation, 95°C for 30 sec; annealing, 56°C for 1 min; and extension, 72°C for 1 min). In addition, the real-time reaction of the products was examined by analyzing the melting point following each reaction. The formula \( \Delta C_{q} = C_{q_{\text{target gene}}} - C_{q_{\text{GAPDH}}} \) was used to determine the \( \Delta C_{q} \) values. Following this initial calculation, \( \Delta C_{q} \) values were calculated using the formula \( \Delta \Delta C_{q} = \Delta C_{q_{\text{treated}}} - \Delta C_{q_{\text{untreated}}} \). Expression of the gene of interest in the treated cells was measured relative to that of the untreated control cells. Results were quantified using the formula 2\(^{-\Delta \Delta C_{q}}\) (18).

**Gas chromatography-mass spectrometry (GC-MS) analysis of crude hexane extract and fraction M\(_{1}\).** Agilent GC-MS (7890A GC, 5975C MS; Agilent Technologies, Inc., Santa Clara, CA, USA) was used for chromatographic analysis. An ionization voltage of 70 eV, injector and detector temperatures of 260°C and 320°C, respectively, and J&W DB-5 MS capillary columns (30 m length, 250 µm internal diameter and 0.25 µm thickness) were used. The oven temperature was initiated at 110°C (isothermal for 5 min), increased to 280°C at 20°C/min (isothermal for 1 min) and increased again to 320°C at 20°C/min (isothermal for 5 min). Helium was the carrier gas and this was used at a flow rate of 1.5 ml/min, with an injector volume of 1 µl with splitless mode. The hexane extract and M\(_{1}\) fraction were dissolved in hexane (1 mg/ml), filtered through 0.2 µm syringe filters (Sigma-Aldrich) and injected into the GC-MS. The mass spectrum of each compound was identified by comparison to the National Institute of Standards and Technology library (http://www.nist.gov/).

**Statistical analyses.** GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis. Results are expressed as the mean ± standard deviation of three independent experiments. One way analysis of variance was performed. The mean ± standard deviation of three independent experiments; cancer cells; normal cells. IC\(_{50}\), half maximal inhibitory concentration.

### Table III. IC\(_{50}\) values of solvent extracts of *Mangifera zeylanica*, mangiferin, paclitaxel and M\(_{1}\) fraction on MCF-7 and MDA-MB-231 breast cancer cell lines, SKOV-3 ovarian cancer cell line and MCF-10A normal mammary epithelial cells.

| Extract/compound       | MCF-7 cells\(^b\) | MDA-MB-231 cells\(^b\) | SKOV-3 cells\(^b\) | MCF-10A cells\(^c\) |
|------------------------|-------------------|-------------------------|-------------------|---------------------|
| Hexane extract, µg/ml  | 87.64±0.37        | 116.5±0.32              | 86.6±0.48         | 217.2±0.33          |
| Chloroform extract, µg/ml | 422.9±0.40      | 280.1±3.44              | 506.5±1.17        | 92.86±0.53          |
| Ethyl acetate extract, µg/ml | >1000            | >1000                   | >1000             | >1000               |
| Methanol extract, µg/ml | >1000             | >1000                   | >1000             | >1000               |
| Mangiferin, µg/ml      | >1000             | >1000                   | >1000             | Not assessed        |
| Paclitaxel, µM         | 0.9959±0.04       | 1.129±0.08              | 0.7807±0.03       | Not assessed        |
| M\(_{1}\) fraction, µg/ml | 28.05±0.84       | 15.42±0.41              | 38.66±0.42        | 114.6±0.32          |

\(^a\)Mean ± standard deviation of three independent experiments; \(^b\)cancer cells; \(^c\)normal cells. IC\(_{50}\), half maximal inhibitory concentration.

### Table IV. Major lipophilic compounds of the hexane extract and M\(_{1}\) fraction obtained from bioactivity-guided fractionation of the hexane extract of *Mangifera zeylanica*, identified by gas chromatography-mass spectrometry analysis.

**A. Hexane extract**

| Retention time, min | Area, % | Compound name                           |
|---------------------|---------|----------------------------------------|
| 6.389               | 0.42    | 3-methyl heptadecane                    |
| 11.454              | 5.64    | Hexacosane                              |
| 13.650              | 0.42    | Campsterol                              |
| 13.816              | 0.47    | Stigmasterol                            |
| 14.222              | 2.90    | \( \beta \)-sitosterol                  |
| 14.224              | 2.90    | \( \gamma \)-sitosterol                 |
| 14.394              | 1.16    | Lanosterol                              |
| 14.892              | 6.76    | 9,19-cyclolanost-24-en-3-ol (cycloartenol) |
| 14.962              | 2.15    | Lanosterol                              |
| 15.026              | 1.21    | \( \beta \)-amyrin                      |
| 16.262              | 6.61    | 4,4-dimethyl-2-nonadecyl-5H-1,3-oxazole |

**B. M\(_{1}\) fraction**

| Retention time, min | Area, % | Compound name                           |
|---------------------|---------|----------------------------------------|
| 3.845               | 6.25    | Unknown                                |
| 4.315               | 1.36    | Unknown                                |
| 4.754               | 19.99   | Unknown                                |
| 5.883               | 3.49    | Olea-2,12-dien-29-oic acid             |
| 5.932               | 4.27    | Unknown                                |
| 6.942               | 1.27    | Unknown                                |
| 14.283              | 10.12   | Unknown                                |
| 22.754              | 1.48    | 2-ethylacridine                        |
| 31.593              | 1.25    | 2-oxo-n-propyl-2-(veratrylidenehydrazino)acetamide |
Figure 1. (A) Cytotoxic activity of the solvent extracts of *Mangifera zeylanica*: Cytotoxic activity of four solvent (hexane, chloroform, ethyl acetate and methanol) extracts of *M. zeylanica* on (a) MCF-7 and (b) MDA-MB-231 breast cancer cell lines and (c) the SKOV-3 ovarian cancer cell line; and (d) cytotoxic activity of hexane and chloroform extracts of *M. zeylanica* on the MCF-10A normal mammary epithelial cell line. (B) Cytotoxic activity of (a) mangiferin, (b) M₁ fraction of *M. zeylanica* and (c) paclitaxel on cancer cell lines (MCF-7, MDA-MD-231 and SKOV-3) and a normal mammary epithelial cell line (MCF-10A). *P<0.05, **P<0.01 and ***P<0.001 vs. control. Data are presented as the mean values from three independent experiments.
with Dunnett’s post hoc test was used to compare groups, and \( P<0.05 \) was considered to indicate a statistically significant difference.

**Results**

**Phytochemical investigation, extract yields, and total polyphenol and flavonoid content in hexane extract of *M. zeylanica* bark.** From 2.5 kg of powdered bark material, 5.20, 5.89, 13.42 and 138.92 g of hexane, chloroform, ethyl acetate and methanol extracts were obtained, corresponding to yields of 0.208, 0.236, 0.5368 and 5.568%, respectively. Qualitative phytochemical investigation revealed that the hexane extract contained steroids, flavonoids, phenolic compounds, tannins and reducing sugars, while saponins were not detected (Table II). The total polyphenolic and flavonoid content in the n-hexane extract was 113.2 mg gallic acid equivalent and 30.4 mg quercetin equivalent, respectively, per 1 g of dried hexane extract.

**Varying levels of cytotoxicity of extracts and *M*₁ fraction are observed in distinct cell lines.** \( IC_{50} \) values of the four solvent extracts of *M. zeylanica* bark, fraction *M*₁, mangiferin and paclitaxel are provided in Table III. Of the four solvent extracts, only the hexane and chloroform extracts demonstrated significant cytotoxicity to all three cancer cell lines in a dose-dependent manner, following 24 h of incubation [MCF-7 (87.64±0.37 µg/ml hexane, \( P<0.0001 \); 422.9±0.40 µg/ml chloroform, \( P<0.0001 \)); MDA-MB-231 (116.5±0.32 µg/ml hexane, \( P<0.0001 \); 280.1±3.44 µg/ml chloroform, \( P<0.0001 \)); SKOV-3 (86.6±0.48 µg/ml hexane, \( P<0.0001 \); 506.5±1.17 µg/ml chloroform, \( P<0.0001 \)) and MCF-10A cells (217.2±0.33 µg/ml hexane, \( P<0.0001 \); 92.86±0.53 µg/ml chloroform, \( P<0.0001 \))]. The hexane extract was highly cytotoxic to the three cancer cell lines and less cytotoxic to normal mammary epithelial cells. By contrast, the chloroform extract was less cytotoxic to the cancer cell lines and highly cytotoxic to normal cells. Mangiferin was not cytotoxic to the cancer cell lines.
investigated in the present study. Fraction M, was strongly cytotoxic to the three cancer cell lines and less cytotoxic to normal cells (Fig. 1A and B). Among the cancer cell lines studied, the highest cytotoxic response was observed in the MDA-MB-231 triple-negative cell line (15.42±0.41 µg/ml).

Apoptosis is induced by the hexane extract of Mangifera zeylanica bark. In response to treatment with the hexane extract, caspase-3 and -7 activity significantly increased in MDA-MB-231 and SKOV-3 cells in a time- and dose-dependent manner (P<0.001) compared with the positive control (ascorbic acid; EC_{50}=4.2 µg/ml); however, caspase-7 was not activated in MCF-7 cells at 4 or 24 h post-incubation (Fig. 2). The EC_{50} values obtained for the hexane extract indicate that it has free radical scavenging activity, although its activity is lower than that of ascorbic acid (values higher than the positive control have a lower activity).

Figure 3. Effect of the hexane extract of Mangifera zeylanica on morphological changes and DNA fragmentation. (A) Morphological observations following acridine orange/ethidium bromide staining in three cancer cell lines treated with the hexane extract for 24 h: (a) MCF-7 cells, (b) MDA-MB-231 cells, and (c) SKOV-3 cells. (a1-c1) control cells; (a2-c2) cells treated with 50 µg/ml; (a3-c3) cells treated with 200 µg/ml; and (a4-c4) cells treated with 400 µg/ml of the hexane extract. (B) DNA fragmentation visualized by 2% agarose gel electrophoresis: M, 100 bp DNA ladder; 1, untreated control; 2, 400 µg/ml hexane extract; 3, 600 µg/ml hexane extract.
chromatin condensation, nuclear fragmentation and changes in the size and shape of cells) in the three cancer cell lines at 24 h post-incubation. DNA fragmentation, a characteristic of late apoptosis, was observed in the three cancer cell lines exposed to the hexane extract for 24 h, with no such evidence observed in control cells (Fig. 3B).

RT-qPCR analysis of p53, Bcl-2-associated X protein (Bax) and survivin genes reveals differential expression of various tumor-associated factors. The relative mRNA expression of the genes investigated in the three cancer cell lines is shown in Fig. 4. RT-qPCR evaluation of cells treated with the hexane extract of *M. zeylanica* bark demonstrated that this extract significantly increased the expression of p53 and Bax mRNA, and decreased the expression of survivin mRNA in MCF-7 cells. In MDA-MB-231 cells, Bax expression was increased; however, p53 and survivin expression were not affected. In SKOV-3 cells, upregulation of Bax and downregulation of survivin was observed.

Hexane extract of *M. zeylanica* bark demonstrates free radical scavenging activity. The DPPH free radical scavenging assay of the hexane extract gave an EC$_{50}$ value of 33.1 µg/ml.

**Phytochemical analysis by GC-MS identifies 11 lipophilic compounds.** GC-MS analysis of the hexane extract of *M. zeylanica* bark tentatively identified 11 lipophilic compounds. The hexane extract was rich in sterols and long-chain hydrocarbons. Compositional analysis of the M$_1$ fraction by GC-MS revealed that it contained 7 unknown compounds along with a small number of known compounds (Table IV).

**Discussion**

Of the four organic extracts of *M. zeylanica* bark, the percentage yield was lowest for the hexane extract. However, the hexane extract was selectively cytotoxic to the cancer cells investigated in the present study and contained secondary metabolites, including flavonoids, tannins, steroids, reducing...
sugars and phenolic compounds, while saponins were absent. The polyphenol content of the hexane extract was greater than the flavonoid content.

The cytotoxicity of the hexane extract to ER-positive (MCF-7) and triple-negative breast cancer cells (MDA-MB-231), and to ovarian epithelial cells (SKOV-3) was dose-dependent, and this extract demonstrated reduced cytotoxicity to normal mammary epithelial cells. By contrast, the chloroform extract demonstrated reduced cytotoxicity in the cancer cells and increased cytotoxicity in the normal cells investigated in the present study. The M<sub>50</sub> fraction, obtained from fractionation of the hexane extract, additionally demonstrated high levels of cytotoxicity in the three cancer cell lines and reduced cytotoxicity in normal mammary epithelial cells. Notably, the highest cytotoxicity was exerted on triple-negative cells. Mangiferin was not observed to exert cytotoxic effects on any of the cancer cell lines investigated in the present study. García-Rivera et al (19) failed to identify any significant cytotoxicity of mangiferin in MDA-MB-231 cells. Thus, compound(s) other than mangiferin in <i>M. zeylanica</i> appear to mediate the cytotoxic and apoptotic effects observed in the present study.

The processes of homeostasis of organs and tissues depends upon the vital role of apoptosis, the dysregulation of which may be observed in cancer (20,21). Apoptosis involves the sequential activation of a cascade of proteases, known as caspases. There are two classes of caspase, initiators and effectors, and the latter class includes caspase-3 and -7 (22). The extrinsic and intrinsic pathways of apoptosis merge to form a common pathway, which is mediated by these effector caspases (23).

In the present study, characteristic features of apoptosis, including activation of caspase-3 and -7 (except in MCF-7 cells), nuclear fragmentation and chromatin condensation were clearly observed in the three cancer cell lines in response to treatment with the hexane extract of <i>M. zeylanica</i> bark. Activation of caspase-7 was not observed in MCF-7 cells, and these cells do not express caspase-3. Thus, it is possible that the hexane extract caused caspase-independent apoptosis in MCF-7 cells through the intrinsic pathway, potentially via activation of apoptosis-inducing factor or endonuclease G, which are responsible for DNA fragmentation (24). Triple-negative breast cancer cells and ovarian epithelial cancer cells demonstrated typical activation of caspase-3 and -7 following exposure to the hexane extract. As the presence of caspase-3 and -7 alone is not able to signify whether the intrinsic or extrinsic pathway has been activated, additional components require investigation in order to ascertain the pathways activated.

Bax and p53 genes have significant roles in apoptosis; increased expression of Bax is known to induce apoptosis (25), while p53, in addition to mediating apoptosis, regulates the antiapoptotic gene survivin (26). In the present study, the upregulation of Bax and p53, with concomitant downregulation of survivin, observed in MCF-7 breast cancer cells in response to the hexane extract suggested that apoptosis in these cells may be mediated via the intrinsic pathway. Triple-negative breast cancer cells, which carry a mutant p53, demonstrated upregulation of Bax, while p53 and survivin expression was not altered in these cells following treatment with the hexane extract; this suggested that a p53-independent pathway may mediate apoptosis in these cells. In the ovarian epithelial cancer cells, which are p53 null, proapoptotic Bax was upregulated and antiapoptotic survivin was downregulated. It is likely that a p53-independent pathway, such as the mitochondria-dependent ‘intrinsic’ cytochrome pathway, is involved in the mediation of apoptosis in these cells (27). The effect of the hexane extract on the activation of caspases and on mRNA expression of proapoptotic and antiapoptotic genes observed in the present study suggested that <i>M. zeylanica</i> exerts its antiproliferative effects, at least partly, via apoptosis; however, the underlying mechanism of apoptosis may differ between the three cancer cell lines investigated.

Oxidants are able to damage DNA and cause mutations, which may lead to carcinogenesis, and are additionally able to stimulate cell division (28). Antioxidants reduce oxidative damage to DNA and reduce aberrant increases in cell division (29). The results of the present study demonstrated that the hexane extract of <i>M. zeylanica</i> possessed antioxidant ability, as revealed by the observed free radical scavenging activity.

GC-MS analysis of the hexane extract identified that it was rich in sterols and long-chain hydrocarbons. β-sitosterol and β-amyrin detected in the hexane extract have been reported to be cytotoxic and apoptosis-inducing compounds in MCF-7 breast cancer cells and HL-60 leukemia cells, respectively (30-32). The M<sub>50</sub> fraction was identified to contain 7 unknown compounds. It additionally contained a small number of known compounds that are not cytotoxic. GC-MS profiles of active fractions gave the present study a strong direction for isolation of phytochemicals from the hexane extract, which is currently being investigated in additional studies.

In conclusion, the results of the present study provide confirmatory evidence for the presence of anticancer compounds in <i>M. zeylanica</i>, an endemic plant used by traditional practitioners in Sri Lanka for the treatment of cancer. Of the two solvent extracts identified to be cytotoxic (hexane and chloroform extracts), the hexane extract demonstrated a greater cytotoxicity in the three cancer cell lines and reduced cytotoxicity in normal mammary epithelial cells. Furthermore, the hexane extract exerted apoptotic and antioxidant effects. The greater cytotoxic effect exerted by the active fraction, particularly on triple-negative cells, warrants additional studies investigating the anticancer effects of <i>M. zeylanica</i>.

Acknowledgements

The present study was supported by the National Research Council (Colombo, Sri Lanka; grant no. NRC 11-018).

References

1. National Breast Cancer Coalition: Ending Breast Cancer: A Baseline Status Report. 2011 Progress Report. National Breast Cancer Coalition, Washington DC, USA, 2011.
2. Rochefort H, Glondu M, Sahla ME, Platet N and Garcia M: How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 10: 261-266, 2003.
3. Li J, Humphreys K, Darabi H, Rosin G, Hannelius U, Heikkinen T, Airomäki K, Blomqvist C, Pharoah PD, Dunning AM, et al: A genome-wide association scan on estrogen receptor-negative breast cancer. Breast Cancer Res 12: R93, 2010.
leaves. Asian Pac J Trop Biomed 2(3): 19.

18. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM and Tattersall MH: On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203-208, 1983.

19. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

20. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

21. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

22. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

23. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

24. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

25. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

26. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

27. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

28. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

29. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

30. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

31. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

32. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

33. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

34. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

35. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

36. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

37. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

38. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

39. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

40. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

41. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

42. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

43. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

44. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

45. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

46. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

47. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

48. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

49. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

50. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

51. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

52. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

53. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

54. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.

55. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.